# A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

> **NCT04300114** · PHASE3 · TERMINATED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04300114
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-19
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor R \& D Strategy Adjustment
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300114, "A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04300114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*